54 related articles for article (PubMed ID: 18323794)
21. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences.
Martín F; Toscano MG; Blundell M; Frecha C; Srivastava GK; Santamaría M; Thrasher AJ; Molina IJ
Gene Ther; 2005 Apr; 12(8):715-23. PubMed ID: 15750617
[TBL] [Abstract][Full Text] [Related]
22. Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector.
Laurie KL; Blundell MP; Baxendale HE; Howe SJ; Sinclair J; Qasim W; Brunsberg U; Thrasher AJ; Holmdahl R; Gustafsson K
Gene Ther; 2007 Dec; 14(23):1623-31. PubMed ID: 17851547
[TBL] [Abstract][Full Text] [Related]
23. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
[TBL] [Abstract][Full Text] [Related]
24. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
[TBL] [Abstract][Full Text] [Related]
25. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS.
Zanta-Boussif MA; Charrier S; Brice-Ouzet A; Martin S; Opolon P; Thrasher AJ; Hope TJ; Galy A
Gene Ther; 2009 May; 16(5):605-19. PubMed ID: 19262615
[TBL] [Abstract][Full Text] [Related]
26. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
[TBL] [Abstract][Full Text] [Related]
27. Wiskott-Aldrich syndrome.
Notarangelo LD; Miao CH; Ochs HD
Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
[TBL] [Abstract][Full Text] [Related]
28. Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
Galy A; Roncarolo MG; Thrasher AJ
Expert Opin Biol Ther; 2008 Feb; 8(2):181-90. PubMed ID: 18194074
[TBL] [Abstract][Full Text] [Related]
29. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Boztug K; Dewey RA; Klein C
Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
[TBL] [Abstract][Full Text] [Related]
30. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.
Breckpot K; Aerts JL; Thielemans K
Gene Ther; 2007 Jun; 14(11):847-62. PubMed ID: 17361214
[TBL] [Abstract][Full Text] [Related]
31. Lentiviral vectors: are they the future of animal transgenesis?
Park F
Physiol Genomics; 2007 Oct; 31(2):159-73. PubMed ID: 17684037
[TBL] [Abstract][Full Text] [Related]
32. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
33. Real-time quantitative PCR for the design of lentiviral vector analytical assays.
Delenda C; Gaillard C
Gene Ther; 2005 Oct; 12 Suppl 1():S36-50. PubMed ID: 16231054
[TBL] [Abstract][Full Text] [Related]
34. The Wiskott-Aldrich syndrome.
Ochs HD; Thrasher AJ
J Allergy Clin Immunol; 2006 Apr; 117(4):725-38; quiz 739. PubMed ID: 16630926
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
